Table 3.
Visit Testing Schedule in the Adalimumab Versus Conventional Immunosuppression (ADVISE) Trial
| Visit Month | Baseline | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 10 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|
| All Patients Testing | ||||||||||
| Medical, ophthalmic, and treatment history | X | X | X | X | X | X | X | X | X | X |
| Best corrected visual acuity on logarithmic visual acuity chart | X | X | X | X | X | X | X | X | X | X |
| Complete eye examinationa | X | X | X | X | X | X | X | X | X | X |
| Optical coherence tomography | X | X | X | X | ||||||
| Color retinal photographs | X | X | X | |||||||
| Quality-of-life instrumentsb | X | X | X | |||||||
| Complete blood cell count and comprehensive metabolic panel | X | X | X | X | X | X | X | X | X | X |
| Pre-immunosuppression blood tests for selected infectionsc | X | |||||||||
| Disease-Specific Testing | ||||||||||
| Intermediate uveitisd: magnetic resonance imaging of the brain | X | |||||||||
| Birdshot chorioretinitis: central and peripheral visual fields | X | X | X | X | X | X | X | X | X | X |
| Chorioditides except birdshot chorioretinitise: fundus autofluorescence | X | X | X | X | X | X | X | X | X | X |
| Retinal vasculitidesf: fluorescein angiography | X | X | X | X | X | X | X | X | X | X |
| Early-stage Vogt-Koyanagi-Harada disease: optical coherence tomography | X | X | X | X | X | X | X | X | X | X |
| Late-stage Vogt-Koyanagi-Harada disease: fundus autofluorescence | X | X | X | X | X | X | X | X | X | X |
Data from the Adalimumab Versus Conventional Immunosuppression (ADVISE) Trial protocol (87).
a Includes slit lamp examination, measurement intraocular pressure, and fundus examination through a dilated pupil.
b Includes Euro-QOL, 36-Item Short-Form Survey, and National Education Institute Visual Function Questionnaire.
c Includes interferon-γ release assay for tuberculosis, hepatitis B surface antigen, and hepatitis C antibody.
d Includes pars planitis and undifferentiated intermediate uveitis to exclude multiple sclerosis (which is worsened by anti-TNF therapy).
e Includes multifocal choroiditis with panuveitis, punctate inner choroiditis, serpiginous choroiditis, relentless placoid choroiditis, sarcoidosis-associated choroiditis, undifferentiated choroiditis, and undifferentiated panuveitis with choroiditis.
f Includes Behçet disease uveitis, undifferentiated retinal vasculitis, and undifferentiated panuveitis with retinal vasculitis.